Lions & Lambs in the Device & DX Industries
Executive SummaryDo big companies differ from small companies only in the size of their resource pool? The different, if not imcompatible perspectives of big and small companies was a recurring theme of the formal sessions and informal discussions at Phoenix '96, a conference for CEOs of medical device and diagnostics companies.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.